This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Catalyst (company) | |
|---|---|
| Name | Catalyst |
| Type | Private |
| Industry | Biotechnology |
| Founded | 2008 |
| Founder | Roger Hankin |
| Headquarters | San Francisco, California |
| Key people | Roger Hankin (CEO), Neha Patel (CTO) |
| Products | Catalytic converters, diagnostic platforms |
| Revenue | Private |
| Num employees | 1,200 (2024) |
Catalyst (company) is a biotechnology and cleantech firm focused on catalytic materials, chemical processes, and diagnostic assays. Founded in 2008 in San Francisco, Catalyst develops catalysts, sensors, and integrated systems for industrial, environmental, and medical applications. The company operates across research, manufacturing, and commercial deployment, engaging with partners in the technology, energy, pharmaceutical, and academic sectors.
Catalyst was established in 2008 by Roger Hankin amid rising interest in renewable energy and materials science, drawing early talent from institutions such as Lawrence Berkeley National Laboratory, Stanford University, and Massachusetts Institute of Technology. In 2010 Catalyst opened its first pilot plant near Palo Alto, California and secured seed investment from venture firms including Kleiner Perkins Caufield & Byers and Sequoia Capital. During the 2010s the firm expanded R&D collaborations with National Renewable Energy Laboratory, Argonne National Laboratory, and the University of California, Berkeley while entering strategic alliances with Shell plc, Dow Chemical Company, and Siemens AG. Catalyst's growth paralleled industry shifts marked by events such as the Paris Agreement and policy incentives from the U.S. Department of Energy, catalyzing contracts with municipal and federal agencies. In the 2020s Catalyst scaled manufacturing, opened facilities in Austin, Texas and Raleigh, North Carolina, and diversified into diagnostics following partnerships with Pfizer and Roche.
Catalyst's portfolio includes heterogeneous catalysts for hydrocarbon processing, electrocatalysts for fuel cells and electrolyzers, and modular diagnostic platforms. Flagship offerings encompass chemical process catalysts sold to clients such as ExxonMobil and BASF SE, and membrane-electrode assemblies licensed to Ballard Power Systems and Plug Power. The company markets air- and water-treatment systems supplied to municipal utilities like New York City Department of Environmental Protection and industrial operators including Dow Chemical Company and General Electric. In the medical sector Catalyst provides point-of-care assay cartridges and automated analyzers used by Mayo Clinic and Kaiser Permanente, supporting panels for infectious disease, oncology markers, and metabolic profiling. Services include custom catalyst formulation, process intensification consulting for firms such as Chevron Corporation, and scale-up manufacturing for contract development and manufacturing organizations like Catalent.
Catalyst's R&D emphasizes nanostructured materials, surface science, and process modeling. Teams collaborate with academic groups at Stanford University and Massachusetts Institute of Technology on topics linked to platinum-group metal reduction, perovskite stability, and single-atom catalysis. The company employs advanced characterization techniques drawing on instruments associated with SLAC National Accelerator Laboratory and Oak Ridge National Laboratory and uses simulation platforms analogous to those from ANSYS and COMSOL Multiphysics to optimize reactor geometries. Catalyst has filed patents covering metal–support interactions, novel electrode architectures, and integrated diagnostic fluidics; licensing and technology transfer occurred with entities such as Johnson & Johnson and Thermo Fisher Scientific. The firm also pilots circular-economy initiatives in collaboration with Veolia for catalyst recovery and precious-metal recycling.
Catalyst operates as a privately held company with a board comprising industry executives and venture investors, including representatives from Kleiner Perkins Caufield & Byers, Sequoia Capital, and strategic partners like Shell plc. The executive team is led by founder and CEO Roger Hankin and CTO Neha Patel, supported by heads of research recruited from Lawrence Berkeley National Laboratory and MIT Lincoln Laboratory. Corporate functions include business development, regulatory affairs, and manufacturing quality systems that interact with standards organizations such as ISO and regulatory bodies like the Food and Drug Administration for diagnostics. The company maintains regional offices in London and Singapore to coordinate European and Asia-Pacific operations.
Catalyst competes in markets alongside Johnson Matthey, Umicore, and Johnson & Johnson across catalysts, clean-energy components, and diagnostics. Revenue details remain private, but disclosures indicate multi-year contractual pipelines with energy majors and healthcare systems. Market drivers include policies stemming from the Inflation Reduction Act and investments influenced by indices such as the S&P 500 and ESG mandates favored by asset managers like BlackRock. Catalyst has completed multiple funding rounds with participation from corporate venture arms including BP Ventures and institutional funds linked to Silver Lake Partners.
Strategic partnerships span energy, industrial, and healthcare sectors. Notable collaborations include joint development with Shell plc on fuel-processing catalysts, licensing deals with Ballard Power Systems for fuel-cell components, and diagnostic pilots with Mayo Clinic and Kaiser Permanente. Catalyst engages academic partnerships with Stanford University, MIT, and the University of California, Berkeley for workforce pipelines and sponsored research. Industrial sales and long-term supply agreements exist with ExxonMobil, BASF SE, and municipal customers such as New York City Department of Environmental Protection and the City of Los Angeles.
Catalyst has received technical awards and recognition from organizations like the U.S. Department of Energy and industry trade groups including the Fuel Cell & Hydrogen Energy Association. The company has been cited in media and trade journals for innovations in single-atom catalysis and diagnostic miniaturization. Controversies include disputes over patent claims with competitors such as Johnson Matthey and regulatory scrutiny in a procurement protest involving a municipal contract in Los Angeles County. Environmental watchdog groups and labor organizations have occasionally criticized production-site permitting and workforce practices, leading to negotiated settlements and revised community engagement programs.
Category:Biotechnology companies Category:Companies based in San Francisco